Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 370

1.

Sildenafil citrate for prophylaxis of nephropathy in an animal model of contrast-induced acute kidney injury.

Lauver DA, Carey EG, Bergin IL, Lucchesi BR, Gurm HS.

PLoS One. 2014 Nov 26;9(11):e113598. doi: 10.1371/journal.pone.0113598. eCollection 2014.

2.

Prothrombotic effects of thrombolytic therapy in a rat (Rattus norvegicus) model of venous thrombolysis.

Shuster KA, Wrobleski SK, Hawley AE, Lucchesi BR, Sorenson DR, Bergin IL, Sigler RE, Guire KE, Nowland MH, Wakefield TW, Myers DD Jr.

Comp Med. 2013 Jun;63(3):244-51.

3.

HBI-3000 prevents secondary sudden cardiac death.

Lee JY, Lucchesi BR.

J Cardiovasc Pharmacol Ther. 2013 Sep;18(5):453-9. doi: 10.1177/1074248413485433. Epub 2013 Apr 23.

PMID:
23615576
4.

Formation, reactivity, and antiplatelet activity of mixed disulfide conjugates of clopidogrel.

Zhang H, Lauver DA, Lucchesi BR, Hollenberg PF.

Mol Pharmacol. 2013 Apr;83(4):848-56. doi: 10.1124/mol.112.084392. Epub 2013 Jan 24.

5.

Oral pretreatment with liposomal glutathione attenuates reperfusion injury in rabbit isolated hearts.

Lauver DA, Kaissarian NM, Lucchesi BR.

J Cardiovasc Pharmacol. 2013 Mar;61(3):233-9. doi: 10.1097/FJC.0b013e31827c0f02.

PMID:
23188132
6.

Hirudin and s18886 maintain luminal patency after thrombolysis with alfimeprase.

Lee JY, Markland FS, Lucchesi BR.

J Cardiovasc Pharmacol. 2013 Feb;61(2):152-9. doi: 10.1097/FJC.0b013e31827aadbc.

PMID:
23188127
7.

Electrolytic inferior vena cava model (EIM) of venous thrombosis.

Diaz JA, Wrobleski SK, Hawley AE, Lucchesi BR, Wakefield TW, Myers DD Jr.

J Vis Exp. 2011 Jul 12;(53):e2737. doi: 10.3791/2737.

8.

Are ECG premature complexes induced by ultrasonic cavitation electrophysiological responses to irreversible cardiomyocyte injury?

Miller DL, Dou C, Lucchesi BR.

Ultrasound Med Biol. 2011 Feb;37(2):312-20. doi: 10.1016/j.ultrasmedbio.2010.11.012.

9.

Thrombogenesis with continuous blood flow in the inferior vena cava. A novel mouse model.

Diaz JA, Hawley AE, Alvarado CM, Berguer AM, Baker NK, Wrobleski SK, Wakefield TW, Lucchesi BR, Myers DD Jr.

Thromb Haemost. 2010 Aug;104(2):366-75. doi: 10.1160/TH09-09-0672. Epub 2010 Jun 29.

10.

Coxibs interfere with the action of aspirin by binding tightly to one monomer of cyclooxygenase-1.

Rimon G, Sidhu RS, Lauver DA, Lee JY, Sharma NP, Yuan C, Frieler RA, Trievel RC, Lucchesi BR, Smith WL.

Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):28-33. doi: 10.1073/pnas.0909765106. Epub 2009 Dec 1.

11.
12.

Estrogen protects the heart from ischemia-reperfusion injury via COX-2-derived PGI2.

Booth EA, Flint RR, Lucas KL, Knittel AK, Lucchesi BR.

J Cardiovasc Pharmacol. 2008 Sep;52(3):228-35. doi: 10.1097/FJC.0b013e3181824d59.

PMID:
18806603
13.

Estrogen-mediated protection in myocardial ischemia-reperfusion injury.

Booth EA, Lucchesi BR.

Cardiovasc Toxicol. 2008 Fall;8(3):101-13. doi: 10.1007/s12012-008-9022-2. Epub 2008 Aug 6. Review.

PMID:
18683081
14.

Disodium disuccinate astaxanthin prevents carotid artery rethrombosis and ex vivo platelet activation.

Lauver DA, Driscoll EM, Lucchesi BR.

Pharmacology. 2008;82(1):67-73. doi: 10.1159/000132085. Epub 2008 May 14.

PMID:
18477858
15.

Thrombostatin FM compounds: direct thrombin inhibitors - mechanism of action in vitro and in vivo.

Nieman MT, Burke F, Warnock M, Zhou Y, Sweigart J, Chen A, Ricketts D, Lucchesi BR, Chen Z, Di Cera E, Hilfinger J, Kim JS, Mosberg HI, Schmaier AH.

J Thromb Haemost. 2008 May;6(5):837-45. doi: 10.1111/j.1538-7836.2008.02937.x. Epub 2008 Feb 25.

16.

Apolipoprotein A-IMilano/POPC complex attenuates post-ischemic ventricular dysfunction in the isolated rabbit heart.

Marchesi M, Booth EA, Rossoni G, García RA, Hill KR, Sirtori CR, Bisgaier CL, Lucchesi BR.

Atherosclerosis. 2008 Apr;197(2):572-8. Epub 2007 Oct 22.

PMID:
17945238
17.

Effects of cyclooxygenase inhibition on canine coronary artery blood flow and thrombosis.

Hong TT, Huang J, Barrett TD, Lucchesi BR.

Am J Physiol Heart Circ Physiol. 2008 Jan;294(1):H145-55. Epub 2007 Oct 5.

18.

The pathway-selective estrogen receptor ligand WAY-169916 reduces infarct size after myocardial ischemia and reperfusion by an estrogen receptor dependent mechanism.

Booth EA, Marchesi M, Knittel AK, Kilbourne EJ, Lucchesi BR.

J Cardiovasc Pharmacol. 2007 Jun;49(6):401-7.

PMID:
17577105
19.
20.

Sulodexide: a renewed interest in this glycosaminoglycan.

Lauver DA, Lucchesi BR.

Cardiovasc Drug Rev. 2006 Fall-Winter;24(3-4):214-26. Review.

21.

Preclinical evaluation of S18886 in an experimental model of coronary arterial thrombosis.

Hong TT, Huang J, Driscoll E, Lucchesi BR.

J Cardiovasc Pharmacol. 2006 Nov;48(5):239-48.

PMID:
17110806
22.

Effect of sodium/hydrogen exchange inhibition on myocardial infarct size after coronary artery thrombosis and thrombolysis.

Hennan JK, Driscoll EM, Barrett TD, Fischbach PS, Lucchesi BR.

Pharmacology. 2006;78(1):27-37. Epub 2006 Apr 3.

PMID:
16899991
23.

Microvascular permeabilization and cardiomyocyte injury provoked by myocardial contrast echocardiography in a canine model.

Miller DL, Driscoll EM, Dou C, Armstrong WF, Lucchesi BR.

J Am Coll Cardiol. 2006 Apr 4;47(7):1464-8. Epub 2006 Mar 15.

24.

Effect of thrombolysis on myocardial injury: recombinant tissue plasminogen activator vs. alfimeprase.

Hong TT, Huang J, Lucchesi BR.

Am J Physiol Heart Circ Physiol. 2006 Mar;290(3):H959-67. Epub 2005 Oct 21.

25.

The antithrombotic effect of melagatran in combination with clopidogrel and/or aspirin (carotid artery primary thrombosis study).

Hong TT, Huang J, Driscoll E, Lucchesi BR.

J Cardiovasc Pharmacol. 2005 Oct;46(4):526-33.

PMID:
16160608
26.

Activation of estrogen receptor-alpha protects the in vivo rabbit heart from ischemia-reperfusion injury.

Booth EA, Obeid NR, Lucchesi BR.

Am J Physiol Heart Circ Physiol. 2005 Nov;289(5):H2039-47. Epub 2005 Jul 1.

27.
28.

Disodium Disuccinate Astaxanthin (Cardax) attenuates complement activation and reduces myocardial injury following ischemia/reperfusion.

Lauver DA, Lockwood SF, Lucchesi BR.

J Pharmacol Exp Ther. 2005 Aug;314(2):686-92. Epub 2005 May 4.

29.

Ischemia depletes dystrophin and inhibits protein synthesis in the canine heart: mechanisms of myocardial ischemic injury.

Rodríguez M, Cai WJ, Kostin S, Lucchesi BR, Schaper J.

J Mol Cell Cardiol. 2005 May;38(5):723-33.

PMID:
15850566
30.
31.

Apolipoprotein A-IMilano and 1-palmitoyl-2-oleoyl phosphatidylcholine complex (ETC-216) protects the in vivo rabbit heart from regional ischemia-reperfusion injury.

Marchesi M, Booth EA, Davis T, Bisgaier CL, Lucchesi BR.

J Pharmacol Exp Ther. 2004 Dec;311(3):1023-31. Epub 2004 Sep 16.

32.

Sulodexide attenuates myocardial ischemia/reperfusion injury and the deposition of C-reactive protein in areas of infarction without affecting hemostasis.

Lauver DA, Booth EA, White AJ, Poradosu E, Lucchesi BR.

J Pharmacol Exp Ther. 2005 Feb;312(2):794-800. Epub 2004 Sep 13.

33.

The preparation and characterization of novel peptide antagonists to thrombin and factor VIIa and activation of protease-activated receptor 1.

Nieman MT, Warnock M, Hasan AA, Mahdi F, Lucchesi BR, Brown NJ, Murphey LJ, Schmaier AH.

J Pharmacol Exp Ther. 2004 Nov;311(2):492-501. Epub 2004 Jun 21.

34.

Risk of ventricular proarrhythmia with selective opening of the myocardial sarcolemmal versus mitochondrial ATP-gated potassium channel.

Fischbach PS, White A, Barrett TD, Lucchesi BR.

J Pharmacol Exp Ther. 2004 May;309(2):554-9. Epub 2004 Jan 27.

35.

17Beta-estradiol as a receptor-mediated cardioprotective agent.

Booth EA, Marchesi M, Kilbourne EJ, Lucchesi BR.

J Pharmacol Exp Ther. 2003 Oct;307(1):395-401. Epub 2003 Jul 31.

36.

Prevention of carotid artery thrombosis after oral administration of the glycoprotein IIb/IIIa antagonist CRL42796.

Hennan JK, Willens DE, Driscoll EM Jr, Hong TT, Giboulot T, Lucchesi BR.

J Cardiovasc Pharmacol. 2003 Jul;42(1):71-7.

PMID:
12827029
38.

SNC-80-induced preconditioning: selective activation of the mitochondrial adenosine triphosphate-gated potassium channel.

Fischbach PS, Barrett TD, Reed NJ, Lucchesi BR.

J Cardiovasc Pharmacol. 2003 May;41(5):744-50.

PMID:
12717105
39.

Apoptosis in myocardial infarction.

Rodríguez M, Lucchesi BR, Schaper J.

Ann Med. 2002;34(6):470-9. Review.

PMID:
12523502
40.

C-reactive-protein-associated increase in myocardial infarct size after ischemia/reperfusion.

Barrett TD, Hennan JK, Marks RM, Lucchesi BR.

J Pharmacol Exp Ther. 2002 Dec;303(3):1007-13.

41.

Prevention of experimental carotid and coronary artery thrombosis by the glycoprotein IIb/IIIa receptor antagonist CRL42796.

Hennan JK, Hong TT, Willens DE, Driscoll EM, Giboulot TA, Lucchesi BR.

Br J Pharmacol. 2002 Jul;136(6):927-37.

42.

Intimatan prevents arterial and venous thrombosis in a canine model of deep vessel wall injury.

Hennan JK, Hong TT, Shergill AK, Driscoll EM, Cardin AD, Lucchesi BR.

J Pharmacol Exp Ther. 2002 Jun;301(3):1151-6.

43.

Thrombostatin inhibits cyclic flow variations in stenosed canine coronary arteries.

Hasa AA, Schmaier AH, Warnock M, Normolle D, Driscoll E, Lucchesi BR, Werns SW.

Thromb Haemost. 2001 Nov;86(5):1296-304.

PMID:
11816721
44.

Conversion of atrial fibrillation by the experimental antiarrhythmic drug tedisamil in two canine models.

Fischbach PS, Barrett TD, Goyal R, Tran BC, Syed ZA, Hennan JK, Lucchesi BR.

J Cardiovasc Electrophysiol. 2001 Oct;12(10):1138-44.

PMID:
11699522
45.

Effects of adenosine on thrombosis and thrombolysis in a canine experimental preparation.

Huang J, Feldbaum VM, Lucchesi BR, Werns SW.

Pharmacology. 2001;63(3):166-74.

PMID:
11598423
46.

Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries.

Hennan JK, Huang J, Barrett TD, Driscoll EM, Willens DE, Park AM, Crofford LJ, Lucchesi BR.

Circulation. 2001 Aug 14;104(7):820-5.

47.
48.

Conditioned blood reperfusion during angioplasty (CoBRA) treatment of acute myocardial infarction.

Patel MB, Kilgore KS, Ortolano GA, Gryboski CL, Qureshi MA, Marcovitz P, Naylor KB, Park JL, Wenz B, Gikakis N, Freedman RJ Jr, Lucchesi BR, O'Neill WW.

Perfusion. 2001 Mar;16 Suppl:39-49.

PMID:
11334205
49.

Tedisamil and dofetilide-induced torsades de pointes, rate and potassium dependence.

Barrett TD, Hennan JK, Fischbach PS, O'Neill BP, Driscoll EM Jr, Lucchesi BR.

Br J Pharmacol. 2001 Apr;132(7):1493-500.

50.

Therapeutic potential of complement inhibitors in myocardial ischaemia.

Lucchesi BR, Tanhehco EJ.

Expert Opin Investig Drugs. 2000 May;9(5):975-91. Review.

PMID:
11060721

Supplemental Content

Loading ...
Support Center